CORE B: The Clinical Ascertainment and Phenotyping Core will establish the clinical and phenotypic classifications which are pivotal for the Program. Core B will also manage all of the biologic resources for the Program. The goal of Core B is to recruit patients and members of families with familial interstitial pneumonia (FIP), to characterize all phenotypes, and obtain the specimens needed to conduct all studies ofthe Program. Core B personnel and facilities will perform the following key functions: 1) patient and family ascertainment, 2) recruitment, 3) phenotyping, 4) database maintenance, 5) specimen acquisition and banking, 6) specimen retrieval and distribution, 7) telomere length analyses. Core B study coordinators at all 3 sites (Vanderbilt, National Jewish/Univ Colorado, and Duke) enter and maintain a detailed database in Progeny Software (Wolfville, Nova Scotia), including pedigree information on each family and phenotype on each individual. Core B laboratory personnel will be responsible for specimen processing, cell culture, storage and management of specimen data. Core B will provide biomaterials (serum, lymphocytes, lymphoblastoids, lung tissue) and high throughput molecular biology services (telomere length analyses) to Program investigators.
Interstitial lung diseases, including the idiopathic interstitial pneumonias, are a substantial cause of morbidity and mortality for which there are no effective treatments. In this program, we will study the genetics and underlying biological mechanisms that lead to progressive fibrosis in the lungs. Our integrated approach will lead to new concepts in disease pathogenesis and identification of novel treatment strategies.
|Molyneaux, Philip L; Willis-Owen, Saffron A G; Cox, Michael J et al. (2017) Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 195:1640-1650|
|Kropski, Jonathan A; Young, Lisa R; Blackwell, Timothy S et al. (2017) Reply: The Genetic Diagnosis of Interstitial Lung Disease: A Need for an International Consensus. Am J Respir Crit Care Med 195:1539-1540|
|Kropski, Jonathan A; Reiss, Sara; Markin, Cheryl et al. (2017) Rare Genetic Variants in PARN Are Associated with Pulmonary Fibrosis in Families. Am J Respir Crit Care Med 196:1481-1484|
|Kropski, Jonathan A; Young, Lisa R; Cogan, Joy D et al. (2017) Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 195:1423-1428|
|Putman, Rachel K; Gudmundsson, Gunnar; Araki, Tetsuro et al. (2017) The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. Eur Respir J 50:|
|Polosukhin, Vasiliy V; Richmond, Bradley W; Du, Rui-Hong et al. (2017) Secretory IgA Deficiency in Individual Small Airways Is Associated with Persistent Inflammation and Remodeling. Am J Respir Crit Care Med 195:1010-1021|
|Allen, Richard J; Porte, Joanne; Braybrooke, Rebecca et al. (2017) Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med 5:869-880|
|Lentz, Robert J; Taylor, Trevor M; Kropski, Jonathan A et al. (2017) Utility of Flexible Bronchoscopic Cryobiopsy for Diagnosis of Diffuse Parenchymal Lung Diseases. J Bronchology Interv Pulmonol :|
|Mathai, Susan K; Newton, Chad A; Schwartz, David A et al. (2016) Pulmonary fibrosis in the era of stratified medicine. Thorax 71:1154-1160|
|Nevel, Rebekah J; Garnett, Errine T; Worrell, John A et al. (2016) Persistent Lung Disease in Adults with NKX2.1 Mutation and Familial Neuroendocrine Cell Hyperplasia of Infancy. Ann Am Thorac Soc 13:1299-304|
Showing the most recent 10 out of 61 publications